Men with Stage IV breast cancer and known estrogen (ER) and progesterone receptor (PR) status benefit from surgical intervention and from trimodal therapy (systemic therapy, surgery, and radiation), according to a study presented at the virtual American College of Surgeons (ACS) Clinical Congress 2021.
The National Comprehensive Cancer Network guidelines to treat men with Stage IV breast cancer recommend systemic therapy, with surgery to be used to minimize symptoms such as ulcerations, pain, or bleeding, said first author Kelly A. Stahl, MD, a surgical resident at Penn State College of Medicine, Hershey. However, new study findings, show that surgery does have survival benefits for men with Stage IV breast cancer, she said.
We need to re-examine the notion that Stage IV breast cancer in men is so dire that there is no survival benefit to surgical intervention.”
Daleela G. Dodge, MD, FACS, general surgeon, Penn State Health Milton S. Hershey Medical Center in Hershey, PA, and co-author of the study
“For this subgroup of patients who are responsive to systemic therapy and do not have a lot of metastatic burden, we’d like there to be a reconsideration of best practices.”
Breast cancer in men accounts for less than 1 percent of all breast cancer cases, whereas one in eight women get breast cancer compared to one in 1,000 men, Dr. Dodge said. As a result, public awareness of breast cancer in men is low.
“We have a whole month devoted to breast cancer awareness for women, but it’s not well known that men can get it, too, and that some men even have a genetic predisposition to getting it,” Dr. Stahl said.
Unfortunately, low public awareness has contributed to the fact that 6 percent of women compared with 10 percent of men are not diagnosed until they have Stage IV cancer. In addition, 40 percent of male breast cancer patients do not get diagnosed until Stages III or IV even though breast cancer is easier for male patients to detect on their own, said Dr. Dodge. She added, “Men have a worse prognosis based on late diagnosis, so awareness is important.”
About the study
The authors were surprised at how many patients they were able to find that fit the parameters of their study, crediting the extensive dataset in the National Cancer Database (NCDB). The researchers identified 539 Stage IV breast cancer patients with known ER/PR status from 2004-2017 in the NCDB. Chi-square tests examined subgroup differences between the treatment modalities received. Overall survival was assessed using the Kaplan-Meier method. Multivariate Cox proportional hazard models examined factors associated with survival.
A noted survival advantage
The researchers found a survival advantage noted in patients who received trimodal therapy compared with patients who received systemic therapy alone. ER positive patients who received trimodal therapy or systemic therapy and surgery had an improved 5-year overall survival rate when compared with systemic therapy. PR positive patients who received trimodal therapy or systemic therapy and surgery had an improved 5-year overall survival rate when compared with systemic therapy. The sequence of treatment was significant, with the greatest survival advantage noted in ER positive patients who received neoadjuvant chemotherapy compared with those who received adjuvant chemotherapy.
“We’re trying to catch up to better tailor our treatment of men with breast cancer and this study shows how treatment can be tailored in Stage IV disease,” Dr. Dodge said.
Business News Governmental News Finance News